Elucid, a Boston, MA-based medical technology company, raised $80M in Series C funding.
The round, which brought the total amount to $121M, was led by Elevage Medical Technologies, with participation from other investors. ì
The company intends to use the funds to expand its commercialization efforts to provide physicians and patients with critical information to combat heart disease.
Led by Blake Richards, CEO, Scott Huennekens, executive chairman, Dr. Todd Villines Chief Medical Officer, Scott Burger, Chief Commercial Officer, Andrew Miller, Chief Technology Officer, Windi Hary, Senior Vice President of Regulatory Affairs and Quality Management, Elucid is a medical technology company dedicated to bringing precision patient care, as currently practiced in oncology, to cardiology. Its AI-powered imaging analysis software is designed to understand the root cause of cardiovascular disease deeply. PlaqueIQ empowers its plaque analysis software, the only FDA-cleared computed tomography angiography (CTA) algorithm that objectively quantifies plaque morphology validated against tens of thousands of tissue annotations by renowned pathologists. Elucid is also pursuing an indication for FFRCT, uniquely derived from its PlaqueIQ technology, to measure coronary blockages non-invasively and the extent of ischemia. It equips physicians with critical information for assessing the risk of plaque rupture in arteries that can lead to heart attack and stroke.
The Elucid plaque analysis software is available for commercial use in the U.S., UK, EU, and South Korea.
FinSMEs
09/11/2023